Addition of camrelizumab improves pathological complete response in early or locally advanced triple negative breast cancer

Increased odds of LV hypertrophy, high relative wall thickness, LV diastolic dysfunction, high LV filling pressure

Higher increase in rates over time seen for Black and Asian patients versus White patients and for Medicaid, Medicare patients

Findings for primary tumors of 0.8 to 1.0 mm versus those <0.8 mm

Highest percentage of patients with HBsAg loss after end of treatment for those receiving xalnesiran + immunomodulator

Two-year cumulative rate of invasive ipsilateral breast cancer 5.9 and 4.2 percent for guideline-concordant care, active monitoring

Significant increase seen in incidence rates at presentation for women overall, and for those aged 20 to 39, 40 to 74, and 75 years or older

Estimated disease-free survival 97.5 ± 1.3 and 90.2 ± 2.3 percent with chemotherapy plus blinatumomab, chemo alone in average-risk patients

Polygenic risk score and polysocial score have independent and additive effects on coronary heart disease

Number of people with at least one episode of HSV-attributable genital ulcer disease was 187.9 and 16.7 million for HSV-2, HSV-1 in 2020